Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.

Autor: Filippova A; Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Irkutsk State Medical University, Ministry of Health of Russia, Irkutsk, Russia., Charles J; Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France., Epaulard O; Infectious Diseases Department, University Hospital of Grenoble, Grenoble, France; Institut de Biologie Structurale, CEA, CNRS, Univ. Grenoble Alpes, Grenoble, France., Germi R; Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Institut de Biologie Structurale, CEA, CNRS, Univ. Grenoble Alpes, Grenoble, France., Persoons V; Cell therapy and engineering Unit, EFS Rhone Alpes, Saint-Ismier, France., Templier I; Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France., Leccia MT; Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France., Dreno B; Oncodermatology department, CIC, CHU, Nantes, France; Immunodermatology lab, CHU, Nantes, France; U 892, INSERM, Nantes, France., Malova I; Irkutsk State Medical University, Ministry of Health of Russia, Irkutsk, Russia., Morand P; Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Institut de Biologie Structurale, CEA, CNRS, Univ. Grenoble Alpes, Grenoble, France., Lupo J; Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Institut de Biologie Structurale, CEA, CNRS, Univ. Grenoble Alpes, Grenoble, France. Electronic address: jlupo@chu-grenoble.fr.
Jazyk: angličtina
Zdroj: Cytotherapy [Cytotherapy] 2018 Apr; Vol. 20 (4), pp. 521-523. Date of Electronic Publication: 2018 Feb 09.
DOI: 10.1016/j.jcyt.2017.12.006
Abstrakt: Exogenous human herpes virus 6 (HHV-6) reinfection has never been reported in patients receiving tumor-infiltrating T lymphocytes therapy. We report an unusual case of HHV-6 infection following infusion of HHV-6 infected autologous T lymphocytes. HHV-6 infection could interfere with the tumor antigen immune recognition and the efficacy of immunotherapy.
(Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: